Organoids and Spheroids Market Report 2026

The organoids and spheroids market size has grown rapidly in recent years. It will grow from $1.39 billion in 2025 to $1.67 billion in 2026 at a compound annual growth rate (CAGR) of 20%. The growth in the historic period can be attributed to early adoption of stem cell technologies, increasing research funding for 3D cell culture, development of organoid culture protocols, rising interest in disease modeling, establishment of specialized biobanks.

The organoids and spheroids market size is expected to see rapid growth in the next few years. It will grow to $3.44 billion in 2030 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to growing demand for personalized medicine, technological advancements in 3D culture methods, expansion of pharmaceutical r&d activities, increasing adoption of organoids in regenerative medicine, rising collaborations between academic institutes and biotech companies. Major trends in the forecast period include increasing adoption of organoids and spheroids in drug discovery, rising use of 3D cell culture models for personalized medicine, growing application of organoids and spheroids in regenerative medicine, rising development of disease-specific organoid and spheroid models, increasing integration of 3D cell models in drug efficacy and toxicity testing.

The growing demand for cell therapy and tissue engineering is expected to drive the expansion of the organoids and spheroids market in the coming years. Cell therapy and tissue engineering involve the use of living cells or engineered tissues to repair, replace, or regenerate damaged tissues and organs. Demand for these approaches is increasing due to their potential to restore damaged tissues and treat previously incurable conditions, offering innovative solutions in regenerative medicine. Organoids and spheroids play a critical role in cell therapy and tissue engineering by modeling complex tissues and testing therapeutic approaches in vitro. For example, in February 2025, according to Cell & Gene, a US-based online resource for research scholars, over 2,500 active INDs for CGTs and around 1,300 active INDs for gene therapies were reported on file with the Office of Therapeutic Products (OTP) in 2023-2024. This rising demand is anticipated to fuel the growth of the organoids and spheroids market.

Companies in the organoids and spheroids market are developing advanced solutions, such as single-particle dispensers, to improve precision in cell handling and enhance reproducibility in research outcomes. Single-particle dispensers are precision instruments that isolate and dispense individual cells or particles, enabling accurate control for research and diagnostic applications. For instance, in July 2024, SEED Biosciences, a Switzerland-based biotechnology company, launched Dispen3D, a device designed for precise dispensing of individual spheroids and organoids. This tool allows researchers to quickly and accurately transfer single spheroids into multi-well plates, automating the procedure while ensuring monoclonality, which is critical for drug discovery and personalized treatments. Dispen3D operates at low pressures to preserve the structural integrity and viability of fragile cells and features a user-friendly design suitable for various research contexts, meeting the growing demand for advanced biological instruments.

In February 2024, Cell Microsystems, a US-based biotechnology company, entered a strategic partnership with OMNI Life Science to enhance life science research in North America. This collaboration focuses on introducing advanced cell analysis tools, including the TIGR Tissue Grinder & Dissociator, the CASY Cell Counter and Analyzer, and the CERO 3D Cell Culture Incubator & Bioreactor. OMNI Life Science, based in Germany, specializes in laboratory instrumentation and solutions for life sciences research.

Major companies operating in the organoids and spheroids market are Thermo Fisher Scientific Inc., Merck KGaA, Corning Incorporated, Lonza Group AG, StemCell Technologies Canada Inc., Greiner Bio-One International AG, Promega Corporation, Molecular Devices LLC, American Type Culture Collection (ATCC), Mimetas B.V., InSphero AG, HUB Organoids, Emulate Inc., 3D Biomatrix Inc., Prellis Biologics Inc., 3D Biotek LLC, DefiniGEN Limited, Visikol Inc., Organovo Holdings Inc., Cellesce Ltd., AMS Biotechnology (Europe) Limited.

North America was the largest region in the organoids and spheroids market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the organoids and spheroids market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the organoids and spheroids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the organoids and spheroids market by increasing costs for imported specialized lab equipment, bioreactor systems, and reagents essential for 3D cell culture. These impacts are most evident in biotechnology and pharmaceutical segments across north america, europe, and asia-pacific, where cross-border supply chains are heavily integrated. Higher tariffs have led to increased operational costs and delays in research timelines. However, tariffs have also encouraged local production of reagents and equipment, boosting regional innovation and supply chain resilience.

The organoids and spheroids market research report is one of a series of new reports that provides organoids and spheroids market statistics, including organoids and spheroids industry global market size, regional shares, competitors with a organoids and spheroids market share, detailed organoids and spheroids market segments, market trends and opportunities, and any further data you may need to thrive in the organoids and spheroids industry. This organoids and spheroids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Organoids and spheroids are three-dimensional cell culture systems that replicate the structure and function of organs and tissues. Organoids are miniaturized, simplified versions of organs derived from stem cells, while spheroids are spherical clusters of cells that can model tumor microenvironments or tissue structures. These systems are widely used for disease modeling and drug testing.

The main types include organoids and spheroids. Organoids are miniature, simplified organ models grown in vitro from stem cells, used to study organ development, disease mechanisms, and drug responses. Methods for generating these models include the extracellular matrix scaffold method, spinning bioreactor method, hanging drop method, low-adherent culture plate method, magnetic levitation method, and others. Applications cover developmental biology, personalized medicine, regenerative medicine, disease pathology studies, and drug toxicity and efficacy testing. End users include biotechnology and pharmaceutical companies, academic and research institutes, and hospitals and diagnostic centers.

The organoids and spheroids market includes revenues earned by entities by providing services such as drug discovery and testing, toxicology screening, personalized medicine, regenerative medicine research, cancer research, stem cell research, and gene editing studies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.